CD19 Knockout Raji/Luciferase Cell Line

Description

CD19 Knockout Raji/Luciferase Cell Line is a genetically engineered B-lymphocyte model derived from Raji cells, featuring dual modifications: stable integration of luciferase (Luc) reporter gene and complete knockout of CD19 expression. This cell line maintains characteristic Raji cell morphology and growth properties while providing sensitive bioluminescence detection for in vivo tumor tracking. The CD19 knockout eliminates target expression for CD19-directed immunotherapies (including CAR-T cells and monoclonal antibodies), making it particularly valuable for studying therapy resistance mechanisms and developing alternative treatment strategies for B-cell malignancies. Cells exhibit stable luciferase expression across passages (<P20) with consistent proliferation rates, enabling reliable longitudinal studies in xenograft models. The cell line is rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, Fungi, Yeast and Bacteria.

Application

• FOR RESEARCH USE ONLY
  

• The CD19 Knockout Raji/Luciferase Cell Line is a genetically engineered B-lymphoma model featuring CD19 gene disruption (via CRISPR/Cas9) with stable luciferase reporter integration. This dual-modified system enables sensitive bioluminescence tracking of tumor progression while serving as an essential tool for studying CD19-independent mechanisms in B-cell malignancies and resistance to CD19-targeted therapies (e.g., CAR-T cells, blinatumomab). Maintain in RPMI-1640 with 10% FBS and appropriate antibiotics for reliable performance in xenograft studies and immunotherapy development applications.